In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment

Molecules. 2024 Apr 23;29(9):1909. doi: 10.3390/molecules29091909.

Abstract

The burden of human schistosomiasis, a known but neglected tropical disease in Sub-Saharan Africa, has been worrisome in recent years. It is becoming increasingly difficult to tackle schistosomiasis with praziquantel, a drug known to be effective against all Schistosoma species, due to reports of reduced efficacy and resistance. Therefore, this study seeks to investigate the antischistosomal potential of phytochemicals from Azadirachta indica against proteins that have been implicated as druggable targets for the treatment of schistosomiasis using computational techniques. In this study, sixty-three (63) previously isolated and characterized phytochemicals from A. indica were identified from the literature and retrieved from the PubChem database. In silico screening was conducted to assess the inhibitory potential of these phytochemicals against three receptors (Schistosoma mansoni Thioredoxin glutathione reductase, dihydroorotate dehydrogenase, and Arginase) that may serve as therapeutic targets for schistosomiasis treatment. Molecular docking, ADMET prediction, ligand interaction, MMGBSA, and molecular dynamics simulation of the hit compounds were conducted using the Schrodinger molecular drug discovery suite. The results show that Andrographolide possesses a satisfactory pharmacokinetic profile, does not violate the Lipinski rule of five, binds with favourable affinity with the receptors, and interacts with key amino acids at the active site. Importantly, its interaction with dihydroorotate dehydrogenase, an enzyme responsible for the catalysis of the de novo pyrimidine nucleotide biosynthetic pathway rate-limiting step, shows a glide score and MMGBSA of -10.19 and -45.75 Kcal/mol, respectively. In addition, the MD simulation shows its stability at the active site of the receptor. Overall, this study revealed that Andrographolide from Azadirachta indica could serve as a potential lead compound for the development of an anti-schistosomal drug.

Keywords: Azadirachta indica; dihydroorotate dehydrogenase; pharmacophore; schistosomiasis; simulation.

MeSH terms

  • Animals
  • Azadirachta* / chemistry
  • Computer Simulation
  • Dihydroorotate Dehydrogenase*
  • Humans
  • Molecular Docking Simulation*
  • Molecular Dynamics Simulation
  • Multienzyme Complexes / antagonists & inhibitors
  • Multienzyme Complexes / metabolism
  • NADH, NADPH Oxidoreductases / antagonists & inhibitors
  • NADH, NADPH Oxidoreductases / metabolism
  • Oxidoreductases Acting on CH-CH Group Donors* / antagonists & inhibitors
  • Oxidoreductases Acting on CH-CH Group Donors* / metabolism
  • Phytochemicals / chemistry
  • Phytochemicals / pharmacology
  • Plant Extracts / chemistry
  • Plant Extracts / pharmacology
  • Praziquantel / chemistry
  • Praziquantel / pharmacology
  • Praziquantel / therapeutic use
  • Schistosoma mansoni / drug effects
  • Schistosoma mansoni / enzymology
  • Schistosomiasis* / drug therapy
  • Schistosomicides / chemistry
  • Schistosomicides / pharmacology
  • Schistosomicides / therapeutic use

Substances

  • Dihydroorotate Dehydrogenase
  • Oxidoreductases Acting on CH-CH Group Donors
  • Phytochemicals
  • thioredoxin glutathione reductase
  • NADH, NADPH Oxidoreductases
  • Plant Extracts
  • Schistosomicides
  • Multienzyme Complexes
  • Praziquantel

Grants and funding

This research received no external funding.